These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28351543)

  • 21. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned.
    Cutler AJ; Tran-Johnson T; Kalali A; Aström M; Brecher M; Meulien D
    Psychopharmacol Bull; 2010; 43(4):37-69. PubMed ID: 21240151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Corrigendum to "Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study" [Schizophr. Res. 239 (2022) 83-91].
    Filts Y; Litman RE; Martínez J; Anta L; Naber D; Correll CU
    Schizophr Res; 2022 Aug; 246():258-259. PubMed ID: 35853294
    [No Abstract]   [Full Text] [Related]  

  • 23. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
    J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Corrigendum to "Facial, vocal and cross-modal emotion processing in early-onset schizophrenia spectrum disorder" [Schizophr. Res. (Aug. 18, 2015) pii: S0920-9964(15)00405-3. doi: 10. 1016/j.schres.2015.07.039].
    M G; J X; A F; N B; C L; D C; L C
    Schizophr Res; 2015 Dec; 169(1-3):508. PubMed ID: 28760563
    [No Abstract]   [Full Text] [Related]  

  • 25. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study.
    Isitt JJ; Nadipelli VR; Kouassi A; Fava M; Heidbreder C
    Schizophr Res; 2016 Jul; 174(1-3):126-131. PubMed ID: 27066860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
    J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Corrigendum to "Morphometric analysis of the cerebral expression of ATP-binding cassette transporter protein ABCB1 in chronic schizophrenia: Circumscribed deficits in the habenula" [Schizophr. Res. 2016 Nov;177(1-3):52-58].
    Bernstein HG; Hildebrandt J; Dobrowolny H; Steiner J; Bogerts B; Pahnke J
    Schizophr Res; 2018 Jul; 197():622-623. PubMed ID: 29636286
    [No Abstract]   [Full Text] [Related]  

  • 28. Corrigendum to "Self and time in individuals with schizophrenia: A motor component?" [Schizophr. Res. 272 (2024) 12-19 (October)].
    Foerster FR; Joos E; Martin B; Coull JT; Giersch A
    Schizophr Res; 2024 Oct; 274():269. PubMed ID: 39395269
    [No Abstract]   [Full Text] [Related]  

  • 29. Corrigendum to "Cognitive-behavioral social skills training for patients with late-life schizophrenia and the moderating effect of executive dysfunction" [Schizophr. Res. 239 (2022) 160-167].
    Rajji TK; Mamo DC; Holden J; Granholm E; Mulsant BH
    Schizophr Res; 2023 Jun; 256():136. PubMed ID: 35787806
    [No Abstract]   [Full Text] [Related]  

  • 30. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.
    Lindenmayer JP; Brown D; Liu S; Brecher M; Meulien D
    Psychopharmacol Bull; 2008; 41(3):11-35. PubMed ID: 18779774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia.
    Redden L; Rendenbach-Mueller B; Abi-Saab WM; Katz DA; Goenjian A; Robieson WZ; Wang Y; Goss SL; Greco N; Saltarelli MD
    J Clin Psychopharmacol; 2011 Apr; 31(2):221-5. PubMed ID: 21346607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Corrigendum to "Natural language processing for defining linguistic features in schizophrenia: A sample from Turkish speakers" [Schizophr. Res. 266 (2024) 183-189].
    Çabuk T; Sevim N; Mutlu E; Yağcıoğlu AEA; Koç A; Toulopoulou T
    Schizophr Res; 2024 Sep; 274():178-179. PubMed ID: 39317121
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study.
    Nasser AF; Henderson DC; Fava M; Fudala PJ; Twumasi-Ankrah P; Kouassi A; Heidbreder C
    J Clin Psychopharmacol; 2016 Apr; 36(2):130-40. PubMed ID: 26862829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
    Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
    J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Corrigendum to "Revisiting the latent structure of negative symptoms in schizophrenia: Evidence from two second-generation clinical assessments" [Schizophr. Res. 248 (2022) 131-139].
    Li SB; Liu C; Zhang JB; Wang LL; Hu HX; Chu MY; Wang Y; Lv QY; Lui SSY; Cheung EFC; Yi ZH; Chan RCK
    Schizophr Res; 2023 Feb; 252():206-207. PubMed ID: 36657365
    [No Abstract]   [Full Text] [Related]  

  • 36. Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder.
    Cantillon M; Prakash A; Alexander A; Ings R; Sweitzer D; Bhat L
    Schizophr Res; 2017 Nov; 189():126-133. PubMed ID: 28215471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
    Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
    Andrezina R; Josiassen RC; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; Iwamoto T
    Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].
    Charpeaud T; Samalin L; Llorca PM
    Encephale; 2014 Feb; 40(1):62-73. PubMed ID: 24445245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.